KKMOH-AG24-BK2

**Borang Penilaian bagi**

**Membangunkan *Clinical Practice Guidelines* (CPG) Baru**

Tajuk Cadangan CPG Baru : ………………………………………………………………………

………………………………………………………………………

Nama Penilai : ………………………………………………………………………

Jawatan : ………………………………………………………………………

**Petunjuk Markah:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1 | 2 | 3 | 4 | 5 |

Low / strongly disagree high / strongly agree

|  |  |  |
| --- | --- | --- |
| **Domain** | **Keterangan** | **Markah** |
| *1. Burden of*  *Disease/Condition* | * *What is the incidence /prevalence of clinical topics (Disease/ condition/ circumstances)?* * *The population (patients, public, etc) to whom the guideline is meant to apply is specifically described?* * *What is the associated mortality and morbidity?* * *What are the rates of relapse, complication, re-admission?* * *Is there reduced quality of life?* * *Is there patient dissatisfaction?* |  |
| *2. Inappropriate / wide variation in clinical practice* | * *Are there gaps between current clinical practice and evidence-based practice?* * *Are significant variations in practice evident?* * *What is the associated risk of the variance from best practice?* * *Would reducing variations incur beneficial effects for patients?* * *Would reducing variations reduce avoidable morbidity and /or mortality?* * *To what extent is there a high risk impact for the health system?* * *Are there high frequency risks factors (avoidable and inherent)?* |  |
| *3. Evidence analysis* | * *Are clinical guidelines recommendations based on an analysis of the evidence?* * *There should be preferably a systematic review of high quality randomized controlled clinical trials or well-designed controlled studies that measure relevant outcomes demonstrating strong, clinically important beneficial public health effects?* * *Is there detail search method and evidence rating?* * *Are recommendations graded based on quality of evidence with explicit link between the recommendations and supporting evidence?* |  |
| *4. Feasibility of*  *implementation* | * *Are there any significant barriers to implementation of the clinical guidelines?* * *How acceptable will the clinical guidelines be to relevant stakeholders (consumers and clinicians)?* * *Is there a degree of urgency for implementation of the guideline?* * *How accessible will the guideline be?* |  |
| *5. Resource Impact* | * *Would implementing this guideline have a substantial budget impact on the healthcare system?* * *Have the resources implications of implementing the guideline been considered?* * *Have the resources required for any initial set up or roll out phase been considered?* * *Have the cost of these resources to the publically funded system been estimated?* * *Are any potential cost savings to be realized if the guideline is implemented?* * *Are any potential cost savings due to changes in the use of resources?*   + *Have the benefits from improved outcomes been quantified and the associated costs or savings been estimated?* * *Is there national or international cost-effectiveness evidence to support the implementation of guidelines?* |  |
| **Markah Keseluruhan** | |  |

Tandatangan,

………………………………………

Tarikh: